Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV003448278 | SCV004175927 | benign | FOXG1 disorder | 2023-10-13 | reviewed by expert panel | curation | The allele frequency of the p.Gln73Pro variant in FOXG1 is 0.027% in the European (non-Finnish) sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Gln73Pro variant is observed in at least 50 unaffected individuals (internal database - GeneDx) (BS2). The p.Gln73Pro variant is found in at least 8 individuals with an alternate molecular basis of disease (internal database - Invitae, internal database - GeneDx) (BP5_Strong). Computational analysis prediction tools suggest that the p.Gln73Pro variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Gln73Pro variant in FOXG1 is classified as Benign based on the ACMG/AMP criteria (BS1, BS2, BP5_Strong, BP4). |
Eurofins Ntd Llc |
RCV000724697 | SCV000224470 | uncertain significance | not provided | 2015-04-07 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000173367 | SCV000613347 | uncertain significance | not specified | 2017-03-07 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000724697 | SCV000728461 | likely benign | not provided | 2020-12-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000648323 | SCV000770139 | benign | Rett syndrome, congenital variant | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Center for Human Genetics, |
RCV000648323 | SCV000781521 | uncertain significance | Rett syndrome, congenital variant | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002426828 | SCV002728618 | likely benign | Inborn genetic diseases | 2018-12-03 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |